12/1 Business Wire Health: Clinical Trials News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Clinical Trials News ChemGenex to Present Positive Data for Omapro™ From Multiple Clinical Trials at ASH November 30, 2009 at 5:30 pm MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center will present Idaho Technology's FilmArray™ Receives Military Funding for CLIA Waiver Effort November 30, 2009 at 5:17 pm SALT LAKE CITY--(BUSINESS WIRE)--The Defense Threat Agency (DTRA), on behalf of the U.S. Air Force Assistant Surgeon General, Modernization Directorate (AF/SGR), has awarded Idaho Technology, Inc. $3.3 million to advance development of the FilmArray™ system and pursue Clinical Laboratory Improvement Amendments (CLIA) waiver from the Food and Drug Administration (FDA). CLIA waiver applies to tests that are simple to perform and interpret, such as rapid Strep tests and pregnancy tests, and c Media Files ViewMedia?mgid=177922&vid=2 (2 KB) PanGenex Signs Licensing Deal to the Enter the $600 Million Spirulla Market November 30, 2009 at 4:39 pm CLEARWATER, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla. Spirulla, a blue green algae, is an abundant and sustainable natural source of protein, essential fatty acids, vitamins, B12 and minerals that has been used as a dietary health supplement for centuries. Through a licensing agreement with Gre Synovis Life Technologies Announces Publication of Veritas® Article in The American Journal of Surgery November 30, 2009 at 4:05 pm ST. PAUL, Minn.--(BUSINESS WIRE)--Synovis Life Technologies, Inc. (Nasdaq: SYNO), a leading biomaterial and surgical products company, announced today that The American Journal of Surgery has published an article on the performance of Synovis’ Veritas® Collagen Matrix for the repair of complex ventral hernias. The lead author is Dr. Jonathan N. Limpert, who describes the outcomes of 26 patients who were treated with Veritas for complex ventral hernias. Veritas is an extremely conforma VELCADE® (Bortezomib) for Injection to be Featured in Plenary Session at American Society of Hematology November 30, 2009 at 3:19 pm CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 5–8, 2009 in New Orleans, Louisiana. These abstracts include an oral presentation of data on successful VELCADE utilization in both induction and maintenance in the front-line setting during the distinguished plenary session being held on Sunday, December 6. T Media Files ViewMedia?mgid=179318&vid=2 (2 KB) Titan Receives Notice of Allowance for Probuphine® Patent Application in the Treatment of Opiate Addiction November 30, 2009 at 1:57 pm SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan’s United States patent application directed to the use of Probuphine for the treatment of opiate addiction. The patent application is U.S. Application No. 10/453,377 filed June 2, 2003 titled “Implantable polymeric device for sustained release of buprenorphine”. The newly Media Files ViewMedia?mgid=206544&vid=2 (2 KB) Resumen: PRA International consigue la acreditación más alta en el programa de Medidata para CRO November 30, 2009 at 11:20 am NUEVA YORK y RALEIGH, Carolina del Norte--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), proveedor líder mundial de soluciones de desarrollo clínico alojadas, ha comunicado que PRA International, organización mundial de investigación clínica (CRO), ha conseguido el estatus Rave Accredited Plus en el programa ASPire to Win® para CROs y otros proveedores de servicios. El nivel más alto del programa, Rave Accredited Plus permite a PRA ofrecer de manera indepe Media Files ViewMedia?mgid=47691&vid=2 (2 KB) Samenvatting: PRA International ontvangt hoogste erkenning in het CRO-programma van Medidata November 30, 2009 at 11:13 am NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), een toonaangevende internationale leverancier van klinische testtoepassingen, maakt vandaag bekend dat PRA International de status Rave Accredited Plus heeft gekregen in het programma getiteld ASPire to Win van Medidata. PRA International is een wereldwijd actieve klinische onderzoeksorganisatie. Met de Rave Accredited Plus, de hoogste rang binnen het programma, kan PRA onafhankelijk zijn klanten het hele pakket aan Media Files ViewMedia?mgid=47691&vid=2 (2 KB) Inovio Partner Announces Completion of Phase I DNA Vaccine Study November 30, 2009 at 9:00 am SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology. The study established the safety and tolerability of this therapy, with vaccine-induced immune responses and transient effects on the serum levels of hepatitis C viru Media Files ViewMedia?mgid=42777&vid=2 (2 KB) U-Systems Introduces Significant Upgrade to Support Ground-Breaking Ultrasound Breast Cancer Screening Study November 30, 2009 at 9:00 am CHICAGO--(BUSINESS WIRE)--U-Systems, Inc., the leader in developing automated breast ultrasound systems, announced a significant upgrade for its somo•v™ Automated Breast Ultrasound System (ABUS) here at the 95th Annual Meeting of the Radiology Society of North America. The INSIGHT Class release incorporates a series of image quality and analysis enhancements designed to better visualize and differentiate complex breast tissue and enable fast and accurate image review. These enhanceme Media Files ViewMedia?mgid=206337&vid=2 (2 KB) PRAインターナショナルがメディデータ・ソリューションズのCRO向けプログラムで 最高レベルの認定を取得 November 30, 2009 at 8:30 am NEW YORK & RALEIGH, N.C.--(BUSINESS WIRE)--ホスト型臨床開発ソリューションのリーディング・グローバル・プロバイダである メディデータ・ソリューションズ（NASDAQ: MDSO）は Media Files ViewMedia?mgid=47691&vid=2 (2 KB) Riassunto: PRA International raggiunge il riconoscimento più elevato nel programma CRO di Medidata November 30, 2009 at 8:30 am NEW YORK e RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), uno dei più importanti fornitori globali di soluzioni ospitate di sviluppo clinico, ha annunciato oggi che PRA International, un'organizzazione di ricerche cliniche (CRO) globale, ha raggiunto la categoria Rave Accredited Plus nel programma ASPire to Win® per CRO e altri fornitori di servizi. Essendo l'ordine massimo raggiungibile nel programma, la categoria Rave Accredited Plus consente a PRA Inter Media Files ViewMedia?mgid=47691&vid=2 (2 KB) PRA International obtient la plus haute accréditation dans le programme de Medidata pour les CRO November 30, 2009 at 8:30 am NEW YORK et RALEIGH, Caroline du Nord--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), un fournisseur mondial de premier plan de solutions hébergées de développement clinique, a annoncé aujourd'hui que PRA International, un organisme de recherche clinique (CRO) mondial, avait obtenu l’accréditation Rave Accredited Plus dans le programme ASPire to Win® pour les CRO et les autres fournisseurs de services. Le niveau le plus élevé du programme, Rave Media Files ViewMedia?mgid=47691&vid=2 (2 KB) PRA International erhält höchste Akkreditierung im Rahmen des CRO-Programms von Medidata November 30, 2009 at 8:30 am NEW YORK und RALEIGH, North Carolina--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), ein führender, weltweit tätiger Anbieter von gehosteten Lösungen für die klinische Entwicklung, teilte heute mit, dass PRA International, ein globales Auftragsforschungsinstitut (CRO), den Status Rave Accredited Plus im Rahmen des ASPire-to-Win®-Programms für CROs und andere Dienstleistungsanbieter erhalten hat. Rave Accredited Plus, die höchste Stufe des Programms, erm Media Files ViewMedia?mgid=47691&vid=2 (2 KB) PRA International Achieves Highest Accreditation in Medidata CRO Program November 30, 2009 at 8:30 am NEW YORK and RALEIGH, N.C.--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical development solutions, today announced that PRA International, a global clinical research organization (CRO), has achieved Rave Accredited Plus status in the ASPire to Win® program for CROs and other service providers. The highest achievable tier in the program, Rave Accredited Plus enables PRA to independently offer its customers a full suite of services around the M Media Files ViewMedia?mgid=47691&vid=2 (2 KB) Xencor Licenses Antibody Optimization Technology November 30, 2009 at 8:00 am MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. (“Centocor”) for the optimization of Centocor’s antibody drug candidates. The license follows a 2009 license agreement that gave Centocor access to Xencor’s proprietary Immunofilte Media Files ViewMedia?mgid=102409&vid=2 (2 KB) ReSearch Pharmaceutical Services, Inc. (RPS) Establishes Global Platform to Capitalize on Outsourced Clinical Trials November 30, 2009 at 8:00 am FORT WASHINGTON, Pa.--(BUSINESS WIRE)--ReSearch Pharmaceutical Services, Inc. (RPS), a next generation contract research organization (CRO) and provider of integrated clinical development outsourcing solutions, today announced the completion of its global platform to provide advanced integrated CRO services across four continents. RPS has positioned itself to capitalize on the growth of global clinical trials. PharmaVoice reported that up to 65% of FDA-regulated clinical trials in the next three Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses November 30, 2009 at 8:00 am NEW YORK & SAN DIEGO--(BUSINESS WIRE)--A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City. The results show that TriGrid™, a technology developed by Ichor Medical Systems, Inc., helped to enhance the immunogenicity of the vaccine tested. Compared to intramuscular injection, the conventional mode o Media Files ViewMedia?mgid=145446&vid=2 (2 KB) Spectrum Pharmaceuticals Announces Completion of Enrollment in One Apaziquone Phase 3 Pivotal Trial for Bladder Cancer Ahead of Schedule November 30, 2009 at 7:00 am IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year. “This is a particularly important milestone for Spectrum and our clinical sites for their unprecedented and remarkabl Media Files ViewMedia?mgid=145348&vid=2 (2 KB)   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.